Our previous finding that normal serum immunoglobulins bind to internal platelet proteins on Western blots led us to further identify these proteins and determine the possible significance of autoantibodies against them. A 95-Kd protein reactive with immunoglobulins in most normal sera and easily confused with gpllla was shown to be a fragment of vinculin generated by calpain proteolysis. Identity was established by peptide sequencing of the protein purified from platelets stored without specific protease inhibitors. Normal immunoglobulins bound intact vinculin (1 17 Kd) and metavinculin (1 5 2 Kd), and their 105-, 95-, and 80-to 85-Kd proteolytic fragments. lgG in 89%. and IgA and IgM in 100% of normal sera reacted in titers of 10 to 1,000 with purified vinculin. In addition, IgG in 79%. and IgA and IgM in 93% of normal sera reacted in titers of 1 0 to 5,000 with talin (235 Kd), another cytoskeletal protein, and its 200-ESTERN BLOTS have been used by others in attempts w to identify platelet proteins reactive with autoantibodies in sera of patients with immune-mediated thrombocytopenias. However, in a series of patients with idiopathic thrombocytopenic purpura (ITP), posttransfusion purpura (PTP), drug purpura, or human immunodeficiency virus (H1V)-associated thrombocytopenia, we have not found autoantibodies detectable by Western blot that differed from those in normal sera, although a high percentage of sera from ITP patients contained autoantibodies against platelet glycoproteins measurable by other techniques.'.2 The present study was undertaken to identify specific platelet proteins reactive with normal sera, and the titers, classes, and possible clinical significance of antibodies against these proteins.
Platelet aggregation and clot retraction.

95-Kdprotein preparation.
Kd proteolytic fragment. lgGs in sera from animals of several different phylogenetic classes also reacted with human vinculin and talin on Western blots. Frequency of occurrence, titers, and classes of antivinculin and antitalin autoantibodies in patients with thrombocytopenia did not differ discernibly from those of normal individuals. These antibodies had no effect on platelet aggregation or clot retraction, and no apparent pathogenic significance, but their widespread presence and the variability in extent of proteolysis of platelet preparations used for Western blots can complicate interpretation of patterns obtained with sera from patients with presumed immune-mediated thrombocytopenias. This is a US government work. There are no restrictions on its use.
taining 150 mmol/L NaCI, 10 mmol/L Tris, pH 7.4, then centrifuged at 4,000g for 30 minutes, and applied to a Q-Sepharose (Pharmacia, Piscataway, NJ) anion-exchange column equilibrated in TBS. Protein was eluted with a 150 to 600 mmol/L NaCl gradient in TBS. Fractions from the first peak were pooled, concentrated, dialyzed against distilled water, and subjected to isoelectric focusing on a Rotofor apparatus (Bio-Rad, Richmond, CA) over an initial pH range of 3.0 to 10.0, using a final concentration of 2% ampholytes. Fractions spanning the pH range of 4.0 to 6.0 were pooled and refocused without further addition of ampholytes. Fractions containing primarily 95-Kd protein (pH 5.5 to 5.7) were pooled, and stored at 4°C with 0.02% NaN3.
The isoelectric point (PI) of this purified protein was determined by horizontal isoelectric focusing; gels were negatively stained with Aurodye (Polysciences, Wanington, PA). Carbohydrate staining was performed with a Glycan Detection Kit (Boehringer-Mannheim, Indianapolis, IN).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the Laemmli method3 on a Bio-Rad minkprotean I1 apparatus as described previously.' Samples to be sequenced were loaded onto gels that had been polymerized overnight and prerun in the presence of reduced glutathione (Sigma). Electrophoresis was performed in the presence of sodium thioglycolate (Sigma) to prevent 746 REID ET AL leupeptin and 2 mmol/L PMSF were added before lysis of platelets, a column of Q-Sepharose (Pharmacia) was used in place of DEAE, and it was eluted with a 20 to 500 mmol/L NaCl rather than 20 to 400 mmol/L NaCl gradient. The gel filtration step was omitted because there was minimal contamination of vinculincontaining fractions with high-molecular weight proteins. Talin eluted from the column in later fractions. Samples were stored at 4°C in elution buffer to which NaN3 was added to a final concentration of 0.02%.
Adsorption of antitalin /rom serum with solid-phase purified tafin. Polystyrene beads, %-in diameter (Pierce, Rockford, IL), were coated overnight at 4°C with purified talin, 1 mg/mL in elution buffer with pH adjusted to 8.8.' Each bead retained approximately 0.5 pg of talin. A normal serum containing antitalin with a titer of 1,OOO was diluted 1/80 in 2.5 mL of phosphate-buffered saline (PBS) and adsorbed two or four times, each time for I hour at 20"C, with IO talincoated beads. Supernatant serum was then diluted to 1/160 with 10' 70 nonfat milk and used to develop a Western blot strip of talin. Reactions were compared with those of unadsorbed serum and of the same serum adsorbed twice with beads coated with bovine serum albumin.
Calpain preparation jiom platelets. Calpain was prepared from outdated platelet concentrates by the method of Schmaier et al with minor modifications? DE-52 was obtained from Whatman, Maidstone, Kent, England. The Reactive Red chromatography step was omitted. Sephacryl S200HR (Pharmacia-LKB) was used for gel filtration in place of Ultrogel AcA 34. Enzyme activity was monitored throughout by a caseinolytic assay in which the test sample in "calpain" buffer containing 50 mmol/L Tris, 50 mmol/L NaCI, pH 7.5, 5 mmol/L EDTA, and 2 mmol/L 2-mercaptwthanol was incubated with casein, 3.3 mg/mL (BDH Chemicals, Poole, England) for 60. minutes at 37°C in the presence of a final concentration of either IO mmol/L EDTA or 5 mmol/L calcium. Protein was precipitated by perchloric acid at a final concentration of IO% on ice for IO minutes and optical densities of supernatants read at 280 nm. One unit of activity was that which caused an increase in optical density of I absorbance unit/mL/hour at 37°C.
Vinculin (-0.5 mg/mL) was exposed at 4°C to purified platelet calpain, 4 U/mL, in calpain buffer adjusted at time 0 to 5 mmol/L Ca2+. Reactions were stopped by addition of SDS-treatment buffer containing IO mmol/L EDTA and immersion .in boiling water for 5 minutes. Calpain inhibitor I (N-Ac-Leu-Leunorleucinal; Boehringer-Mannheim), which inhibits both calpain I and 11, was used at a final concentration of 200 pg/mL.
Platelets washed in saline-EDTA were stored at a concentration of IO6 plateletslpl at 4°C in saline or PBS with or without IO mmol/ L EDTA and/or 200 pg/mL calpain inhibitor I. Samples from each were taken periodically over a period of 5 days, electrophoresed, and checked for breakdown products of vinculin using monoclonal antivinculin.
Reagents. Monoclonal antivinculin and antitalin, both raised against the respective chicken gizzard proteins, and antigelsolin against human plasma gelsolin were from Sigma. Polyclonal rabbit anti-human platelet talin was a gift from Dr Otey Western blot reactions of human and animal sera with purijied human and chicken vinculin. Figure 4 shows the reactions of monoclonal antivinculin (lane I), examples of reaction intensity of four normal human sera diluted I / IO (lanes 2 through 4 and 8), of two preparations of purified human IgG (lanes 5 and 6), and of purified human IgA (lane 7) with human platelet vinculin. Of 28 normal sera assayed for reactivity to purified vinculin (Table I) , 89% had IgG, 100% IgA, and 100% Igh4 antibodies with titers ranging from IO to 1,OOO for IgG and IO to 500 for IgA and IgM. The intensity of reactions of sera diluted 1/10 from patients with various thrombocytopenic disorders (examples in lanes 9 through I7), varied similarly to that of normal sera.
Proteolysis experiments.
RESULTS
Demonstration
Sera from chickens, guinea pigs, rabbits, sheep, and rhesus monkeys, each at 1/10 dilution, reacted on Western blots with purified human vinculin; murine serum did not. Titers of reactive sera did not exceed 100. Mouse, chicken, guinea pig, and rabbit sera were pooled samples from many animals; the others were obtained from individual animals.
Preincubation of Western blots of human purified vinculin with either of two normal human sera containing antivinculin titers of 1,000 (dilution-') and used at 1/10 dilution blocked subsequent binding of a mouse monoclonal antivinculin with a titer of 50,000 used at 1/330 dilution, but preincubation with the mouse antivinculin did not block binding of the Talin  Patient   1  2  3  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26 ITP  50  1  500  2  20  3  20  4  100  5  100  6  50  7  20  8  100  HIV  50  1  50  2  50  3  20  4  200  SLE  20  1  50  2  100  AA  100  1  500  2  100  MF  200  1  10  PTP  40  1  100  2  200  Qd  100  1 235 Kd) and its major proteolytic fragment (mol wt, 200 Kd) can be obscured by a broad background band at approximately 200 Kd, which represents platelet-associated IgG.' Therefore, purified talin, rather than solubilized platelets, was used to assess reactivities of normal sera.
Western blot reactions of human and animal sera with purged human platelet talin. Of 28 normal sera screened by Western blot for antitalin, 22 (79%) had IgG, 26 (93%) IgA, and 26 (93%) IgM antibodies. IgG titers (dilution-') ranged from 0 to 5,000, IgA from 0 to 2,000, and IgM from 0 to 1,000 (see Table 1 ). Minimal concentrations of commercial purified immunoglobulins required for reactions with purified talin on Western blot were 0.025 mglmL for IgG (Cappel lot 30410), 0.06 mglmL for F(ab')2 (Cappel lot 33779), 0.25 mgl mL for IgA (Sigma lot 69F-3922), and 0. IO mg/mL for IgM (Calbiochem lot 003904).
Serum containing an antitalin titer of 1,000 lost 50% of its titer after adsorbed twice with talin-coated beads and lost 90% after fourfold adsorption. Adsorption with albumincoated beads did not change the titer.
Of eight patients with ITP (one acute and seven chronic), 63% had IgG, 100% IgA, and 100% IgM antibodies reactive with human platelet talin. Titers on Westem blot ranged from IO to 1,000 for IgG, 200 to 1,OOO for IgA, and 10 to 1,000 for IgM. Antitalin and antivinculin titers ofsera from thrombocytopenic patients with disorders other than ITP are listed in Table I. Of chicken, mouse ,guinea pig, rabbit, goat, dog, and chimp sera assayed at 1/20 dilution, chicken, guinea pig, rabbit, and goat sera were reactive with human talin. Titers did not exceed 100.
Titers ofantivinculin and antitalin immunoglobulin classes in the same individuals. Twenty-eight normal sera chosen randomly from the 100 sera reported previously' were assayed for IgG, IgA, and IgM antibodies to talin and vinculin, and the results are listed in Table I . Results of similar studies of sera from thrombocytopenic patients are also listed. There does not appear to be any correlation between the presence of antivinculin and antitalin antibodies or respective IgG, IgA, or IgM titers within the same individual. In thrombocytopenic patients, titers and classes of antibodies to these proteins did not differ discernibly from those of normal individuals or correlate with platelet count.
Shape change and aggregation responses to ADP (20 pmol/L), collagen (0.2 mg/mL), and epinephrine (10 pmol/L) were normal in two individuals whose sera contained high titers (1 : 1,000) ofantivinculin and in two individuals with similar titers of antitalin. Clot retraction of recalcified PRP was also normal in these four individuals.
Platelet aggregation.
DISCUSSION
Reactions osnorma1 sera with vinculin and its proteolytic products. We previously reported that normal serum im- Fig 2) ; and ( 5 ) the sequence of an internal peptide exactly matching amino acids 140 to 162 of human vinculin. ' Of 28 normal sera, 89% had IgG, 100% IgA, and 100% IgM antibodies reactive with purified vinculin at titers ranging from 10 to 1,000 for IgG and 10 to 500 for IgA and IgM. Normal human and animal sera react with an epitope in the 80-to 1 IO-Kd N-terminal domain of vinculin and metavinculin, which is preserved in the major proteolytic fragments produced by calpain. Calpains account for 95% of platelet neutral protease activity.' ' Proteolysis of vinculin in saline suspensions of platelets probably occurs extracellularly, because it can be inhibited by calpain inhibitors I and 11, which are not membrane-permeable (see Fig 2) , and most of the proteolyzed vinculin can be removed from platelet suspensions by washing.
Reactions of normal sera with talin and its proteolyticfiagment. Of 28 normal sera, 22 (79%) had talin-reactive IgG antibodies and eight of the 22 had titers greater than 500,26 (93%) had talin-reactive IgA antibodies and 26 (93%) had IgM antibodies. A 200-Kd fragment of talin, which can be generated by calpain during platelet lysis in the absence of EDTA or specific calpain inhibitors,I2 retained the target epitope(s) of intact platelet talin (235 Kd) as evidenced by similar reactivities of sera and monoclonal antibodies with both For personal use only. on October 23, 2017. by guest www.bloodjournal.org From components (see Fig 5, lanes 4 and 5) . Antitalin reactions at 235 and 200 Kd may have been overlooked on Western blots in the past, because platelet-associated IgG can elicit a broad and often dense background band at approximately 200 Kd (see Fig I , lane 3) .
Characteristics of naturally occurring autoantibodies to cytoskeletal proteins. Although normal sera contain antivinculin immunoglobulins in titers up to approximately 1,000, most do not exceed 50.' Antitalin antibodies of normal sera also tend to be low in titer. These data are consistent with two other recent report^.'^,'^ Antibodies that have been described in normal sera against other intracellular cytoskeletal proteins, including tubulin, actin, desmin, and vimentin, are usually low-avidity, polyspecific, and of the IgM lass.'^-^' Antibodies against both vinculin and talin include all major immunoglobulin classes with about equal frequency and appear to be monospecific. Antivinculin antibodies that we have tested were more avid than hyperimmune monoclonal antibodies as evidenced by competitive displacement, while antitalin antibodies seemingly have low avidity based on their degree of adsorption to excess solid-phase talin (see Results).
Sera from animals of different phylogenetic classes reacted with human vinculin and talin with maximum titers (IgG) of 100. Chicken and human sera reacted with purified chicken vinculin, which has a 95% amino acid sequence identity with human vinculin. ' Platelet shape change and aggregation and clot retraction, which may be influenced by an indirect effect of vinculin and talin on F-actin micr~filaments,l~-~~ was normal in individuals with high titers of antivinculin or antitalin, and normal individuals with normal platelet function have had some of the highest-titer antibodies observed. This is in keeping with findings that neither protein is exposed on the surface of unactivated or activated platelets. 25 Problems using Western blots for detecting antibodies in immune-mediated thrombocytopenias. Western blots used in attempts to identify platelet-specific antibodies in sera of patients with a variety of thrombocytopenic disorders may have been misinterpreted in some instances because of reactions of naturally occumng antibodies against vinculin and talin. Since membrane proteins gpIIb (140 Kd)/IIIa (90 Kd) and gpIb (1 70 Kd)/IX(22 Kd) have been identified by antigen capture assays as target antigens of autoantibodies in ITP,26,27 bands elicited by ITP sera on Western blots close to these levels generally have been considered to represent specific reactions with these glycoproteins. However, particular confusion can arise from the marked similarity of Western blot band positions of gpIIIa and the 95-Kd fragment of vinculin; when reduced, gpIIIa at an apparent molecular weight of 1 10 Kd might be mistaken for intact 120-Kd vinculin. In our experience, none of 10 sera from thrombocytopenic ITP patients reacted with gpIIIa on Western blot, but eight of the 10 reacted with vinculin, just as did normal sera. Four of these same ITP sera reacted with gpIIIa in an immunobead assay,2 indicating that Western blot is usually too insensitive to detect the gpIIIa reactions associated with ITP. A report that IgG in acute serum from a patient with posttransfusion purpura reacted with a 120-Kd protein suggested that the autoantibody might have been responsible for thrombocytopenia because recovery-phase serum did not contain the antibody." Equally plausible is the possibility that intact vinculin in platelets used to test the initial sample produced a "normal" 120-Kd band, and proteolyzed vinculin in platelets used with the follow-up sample produced a 95-Kd "normal" band that was obscured by the patient's strong antiPlAl reaction with gpIIIa. Care must be taken to assure that antivinculin and antitalin are not mistaken for pathogenic antibodies.
We did not find higher titers of antivinculin or antitalin in patients with immune thrombocytopenias than in normal persons, although this has recently been reported.14 We found no relationship between platelet count and antibody titer and no evidence that these antibodies adsorb to intact platelets or affect platelet function. Since vinculin and talin are major components of a variety of cell^,^^"^ platelet-derived material may not be the source of sensitizing antigens. Questions raised by these observations are whether reactivity with vinculin and talin represents cross-reactions of antibodies against other common antigens, whether the high frequency of IgA antibodies reflects mucosal sensitization, and why naturally occurring antibodies against evolutionarily conserved cytoskeletal proteins are prevalent in many phylogenetic classes.
